Drugs / Crefmirlimab Berdoxa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05279027 | Mar 2022 → May 2025 | cutaneous melanoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crefmirlimab Berdoxa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05279027 ↗ |
| Route | Other | “subjects will be injected with Zirconium Zr 89 Crefmirlimab Berdoxa up to 8 days prior to starting therapy” NCT05279027 ↗ |